Acetyl-L-Carnitine (ALC) in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial.

Acetyl-L-Carnitine (ALC) in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Acetyl-L-Carnitine (ALC) in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial. Abstract Text:

L Eugene Arnold,Antonino Amato,Hernan Bozzolo,Jill Hollway,Amy Cook,Yaser Ramadan,Lindsay Crowl,Dan Zhang,Susan Thompson,Giussepe Testa,Vernon Kliewer,Timothy Wigal,Keith McBurnett,Michael Manos,

Objective: To determine whether acetyl-L-carnitine (ALC), a metabolite necessary for energy metabolism and essential fatty acid anabolism, might help attention-deficit/hyperactivity disorder (ADHD). Trials in Down's syndrome, migraine, and Alzheimer's disease showed benefit for attention. A preliminary trial in ADHD using L-carnitine reported significant benefit. Method: A multi-site 16-week pilot study randomized 112 children (83 boys, 29 girls) age 5-12 with systematically diagnosed ADHD to placebo or ALC in weight-based doses from 500 to 1500 mg b.i.d. The 2001 revisions of the Conners' parent and teacher scales (including DSM-IV ADHD symptoms) were administered at baseline, 8, 12, and 16 weeks. Analyses were ANOVA of change from baseline to 16 weeks with treatment, center, and treatment-by-center interaction as independent variables. Results: The primary intent-to-treat analysis, of 9 DSM-IV teacher-rated inattentive symptoms, was not significant. However, secondary analyses were interesting. There was significant (p = 0.02) moderation by subtype: superiority of ALC over placebo in the inattentive type, with an opposite tendency in combined type. There was also a geographic effect (p = 0.047). Side effects were negligible; electrocardiograms, lab work, and physical exam unremarkable. Conclusion: ALC appears safe, but with no effect on the overall ADHD population (especially combined type). It deserves further exploration for possible benefit specifically in the inattentive type.

Acetyl-L-Carnitine (ALC) in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial. Publishing Authors By Initials

LE Arnold,A Amato,H Bozzolo,J Hollway,A Cook,Y Ramadan,L Crowl,D Zhang,S Thompson,G Testa,V Kliewer,T Wigal,K McBurnett,M Manos,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Acetyl-L-Carnitine (ALC) in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of child and adolescent psychopharmacology

VOLUME: 17

Page Numbers: 791-802

Journal Abbreviation:

ISSN: 1044-5463

DAY: 4

MONTH: Dec

YEAR: 2007

Acetyl-L-Carnitine (ALC) in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9105358

Acetyl-L-Carnitine (ALC) in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Acetyl-L-Carnitine (ALC) in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Acetyl-L-Carnitine (ALC) in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial.

AFFILIATION: The Ohio State University Nisonger Center, Columbus, OH.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Child Adolesc Psychopharmaco

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Acetyl-L-Carnitine ALC in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial Related Publications

• A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris.
• Acetyl-L-Carnitine (ALC) in Attention-Deficit/Hyperactivity Disorder: A Multi-Site, Placebo-Controlled Pilot Trial.
• Deconvolution filters to enhance resolution of dense time-of-flight survey spectra in the time-lag optimization range.
• Differential emotional precipitation of migraine and tension-type headache attacks.
• Histoplasmin sensitivity conversion rates.
• Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm.
• Pharmacologic Treatment of ADHD: Road Conditions in Driving Patients to Successful Outcomes.
• Psychosis Associated with Anti-N-methyl-D-aspartate Receptor Antibodies.
• Resampling and deconvolution of linear time-of-flight records for enhanced protein profiling.
• The outcomes of lumbar microdiscectomy in a young, active population: correlation by herniation type and level.
• Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder.